Advanced Viral Research CP (ADVR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Advanced Viral Research CP (ADVR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sunny Chu who wrote (1876)	12/13/1996 11:57:00 PM
From: Mark Chavez	of 2281

Sunny - some of your points are valid, some are not. The staff of a biotech company can be small and typically is for a single product. A single product is also okay, but riskier. With a limited staff (<10) and a single product, getting to phase II trials is certainly possible and it has been done numerous times. There is more than one blueprint to a successful business. Positives for ADVR include a product that seems to show efficacy and safety, negatives include a large cash burn rate, low R&D, poor management to date, no patent protection (this is a drug, not a soft drink). Anyway, here's a good read on biotech stock investing for those interested: tandemcap.com Good luck Mark.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next